Go to main content
Type 1
Type 2

New Trial Data Shows Once-Weekly Insulin Improves Time in Range

Clinical trial results found that the once-weekly insulin icodec helped participants with type 2 diabetes stay in their target blood glucose range. The data also shows that once-weekly basal insulins are just as effective at reducing A1C as once-daily insulin. 

Novo Nordisk shared exciting new findings about a once-weekly insulin called icodec at the 83rd ADA’s Scientific Sessions this week.

Results from phase 3a of the ONWARDS 1 and ONWARDS 3 clinical trials showed that more people with type 2 diabetes achieved their blood sugar targets – without experiencing severe hypoglycemia – with once-weekly insulin compared to once-daily insulin. In both trials, icodec had similar glucose-lowering effects to once-daily basal insulin and reduced the number of weekly injections from seven to one. 

Study data demonstrated that participants spent more time in range (blood glucose 70-180 mg/dL) taking once-weekly insulin, and a higher proportion reached an A1C target of less than 7% (the goal for most adults living with diabetes, according to the ADA) without an increase in moderate or severe hypoglycemia.

"A once-weekly basal insulin has the potential to change how we treat people with type 2 diabetes needing basal insulin replacement," said Dr. Julio Rosenstock, lead investigator and clinical professor of medicine at the University of Texas Southwestern Medical Center, in a press release.

Since both trials have met their primary goals, Novo Nordisk has submitted a new drug application for icodec to the FDA, bringing it one step closer to the market.

Learn all about insulin treatments here: